Internal Reference Number: FOI_8830
Date Request Received: 07/08/2025 00:00:00
Date Request Replied To: 18/08/2025 00:00:00
This response was sent via: By Email
Request Summary: treatment of Haemophilia A
Request Category: Companies
| Question Number 1: How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Mild - >5 Moderate - <5 Severe - <5 | |
| Question Number 2: In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Marstacimab • CEVENFACTA • Any other products | |
| Answer To Question 2: Altuvoct - 0 • Advate - 0 • Adynovi - 0 • Elocta - <5 • Esperoct 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) - 0 • Hemlibra (standalone) - 0 • Hemlibra in combination with any Factor VIII - 0 • NovoEight - 0 • NovoSeven RT - 0 • Nuwiq - 0 • Obizur - 0 • Refacto AF - 0 • Marstacimab - 0 • CEVENFACTA - 0 • Any other products - 0 | |
| Question Number 3: For patients treated with Advate in the last three months, please provide: • The number of haemophilia A patients treated prophylactically • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) | |
| Answer To Question 3: • The number of haemophilia A patients treated prophylactically - 0 • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) - 0 | |
| Question Number 4: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Marstacimab • CEVENFACTA • Any other products | |
| Answer To Question 4: • Altuvoct - 0 • Advate - 0 • Adynovi - 0 • Elocta - <5 • Esperoct - 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) - 0 • Hemlibra (standalone) - 0 • Hemlibra in combination with any Factor VIII - 0 • NovoEight - 0 • NovoSeven RT - 0 • Nuwiq - 0 • Obizur - 0 • Refacto AF - 0 • Marstacimab - 0 • CEVENFACTA - 0 • Any other products - 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
